224 related articles for article (PubMed ID: 21778901)
1. Diffuse uremic tumoral calcinosis in a patient on long-term hemodialysis.
Akasbi N; Houssaini TS; Rabhi S; Lahlou M; Boukhrissa A; Tahiri L; El Maaroufi C; Berrady R; Harzy T; Bono W
J Clin Rheumatol; 2011 Aug; 17(5):272-4. PubMed ID: 21778901
[TBL] [Abstract][Full Text] [Related]
2. Sevelamer hydrochloride attenuates kidney and cardiovascular calcifications in long-term experimental uremia.
Cozzolino M; Staniforth ME; Liapis H; Finch J; Burke SK; Dusso AS; Slatopolsky E
Kidney Int; 2003 Nov; 64(5):1653-61. PubMed ID: 14531797
[TBL] [Abstract][Full Text] [Related]
3. Effect of sevelamer and calcium-based phosphate binders on coronary artery calcification and accumulation of circulating advanced glycation end products in hemodialysis patients.
Kakuta T; Tanaka R; Hyodo T; Suzuki H; Kanai G; Nagaoka M; Takahashi H; Hirawa N; Oogushi Y; Miyata T; Kobayashi H; Fukagawa M; Saito A
Am J Kidney Dis; 2011 Mar; 57(3):422-31. PubMed ID: 21239096
[TBL] [Abstract][Full Text] [Related]
4. Cervical tumoral calcinosis with secondary hyperparathyroidism in a chronic hemodialysis patient.
Sunder S; Verma H; Venkataramanan K
Hemodial Int; 2013 Jul; 17(3):458-62. PubMed ID: 23072397
[TBL] [Abstract][Full Text] [Related]
5. Tumoral calcinosis, calciphylaxis, hyperparathyroidism and tuberculosis in a dialysis patient.
Kammoun K; Jarraya F; Hmida MB; Khebir A; Kharrat M; Boudawara T; Mnif J; Hachicha J
Saudi J Kidney Dis Transpl; 2011 Mar; 22(2):306-10. PubMed ID: 21422631
[TBL] [Abstract][Full Text] [Related]
6. [Effect of non-calcium-based phosphate binders on vascular calcifications in patients on hemodialysis: clinical experience and hypotheses].
Bolasco P
G Ital Nefrol; 2011; 28(4):357. PubMed ID: 21809303
[No Abstract] [Full Text] [Related]
7. [Tumorous calcinosis in hemodialysis: anatomo-clinical study apropos of 3 cases].
Ben Taarit C; el Younsi F; Turki S; Mestiri M; Zlitni M; Ben Maïz H
Nephrologie; 2001; 22(7):349-52. PubMed ID: 11817212
[TBL] [Abstract][Full Text] [Related]
8. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
9. Uremic tumoral calcinosis in hemodialysis patients: clinicopathological findings and identification of calcific deposits.
Hamada J; Tamai K; Ono W; Saotome K
J Rheumatol; 2006 Jan; 33(1):119-26. PubMed ID: 16395759
[TBL] [Abstract][Full Text] [Related]
10. Effects of sevelamer on the progression of vascular calcification in patients on chronic haemodialysis.
Takei T; Otsubo S; Uchida K; Matsugami K; Mimuro T; Kabaya T; Akiba T; Nitta K
Nephron Clin Pract; 2008; 108(4):c278-83. PubMed ID: 18434749
[TBL] [Abstract][Full Text] [Related]
11. Uremic tumoral calcinosis in patients receiving longterm hemodialysis therapy.
Cofan F; García S; Combalia A; Campistol JM; Oppenheimer F; Ramón R
J Rheumatol; 1999 Feb; 26(2):379-85. PubMed ID: 9972973
[TBL] [Abstract][Full Text] [Related]
12. Resolution of massive uremic tumoral calcinosis with daily nocturnal home hemodialysis.
Kim SJ; Goldstein M; Szabo T; Pierratos A
Am J Kidney Dis; 2003 Mar; 41(3):E12. PubMed ID: 12613005
[TBL] [Abstract][Full Text] [Related]
13. Blockage of the renin-angiotensin system attenuates mortality but not vascular calcification in uremic rats: sevelamer carbonate prevents vascular calcification.
Tokumoto M; Mizobuchi M; Finch JL; Nakamura H; Martin DR; Slatopolsky E
Am J Nephrol; 2009; 29(6):582-91. PubMed ID: 19145073
[TBL] [Abstract][Full Text] [Related]
14. [Posttransplant regression of uremic tumoral calcinosis].
de Alarcón RM; Palomares M; Marfil A; Asensio C
Nefrologia; 2007; 27(3):378-81. PubMed ID: 17725459
[TBL] [Abstract][Full Text] [Related]
15. Switching from calcium carbonate to sevelamer hydrochloride has suppressive effects on the progression of aortic calcification in hemodialysis patients: assessment using plain chest X-ray films.
Izumi M; Morita S; Nishian Y; Miyamoto T; Kasumoto H; Oue M; Hori K; Kitamura R; Yamamoto S; Nakanishi T
Ren Fail; 2008; 30(10):952-8. PubMed ID: 19016145
[TBL] [Abstract][Full Text] [Related]
16. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. No good evidence to promote a general use of sevelamer.
Nguyen QV; Descombes E
Kidney Int; 2008 Jan; 73(2):238-9, author reply 239. PubMed ID: 18165813
[No Abstract] [Full Text] [Related]
17. Massive, painful tumoral calcinosis in a long-term hemodialysis patient.
Carvalho M; de Menezes IA; Riella MC
Hemodial Int; 2011 Oct; 15(4):577-80. PubMed ID: 22093521
[TBL] [Abstract][Full Text] [Related]
18. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients.
Block GA; Raggi P; Bellasi A; Kooienga L; Spiegel DM
Kidney Int; 2007 Mar; 71(5):438-41. PubMed ID: 17200680
[TBL] [Abstract][Full Text] [Related]
19. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis.
Block GA; Spiegel DM; Ehrlich J; Mehta R; Lindbergh J; Dreisbach A; Raggi P
Kidney Int; 2005 Oct; 68(4):1815-24. PubMed ID: 16164659
[TBL] [Abstract][Full Text] [Related]
20. Vascular calcification and QT interval in incident hemodialysis patients.
Di Iorio BR; Cucciniello E; Bellizzi V
J Nephrol; 2009; 22(6):694-8. PubMed ID: 19967647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
